MedTrace Logo

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

NCT02794961 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-06-09

No results posted yet for this study

Summary

CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.

Conditions

  • Recurrent or Refractory B Cell Malignancy

Interventions

BIOLOGICAL

CD22 CAR-T

Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight

Sponsors & Collaborators

  • iCarTAB BioMed Inc.

    collaborator UNKNOWN

  • Kai Lin Xu; Jun Nian Zheng

    lead OTHER

Principal Investigators

  • KaiLin Xu, MD. Ph.D. · Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02794961 on ClinicalTrials.gov